VALIDOGEN - News

101 16.10.2023

VALIDOGEN is giving UNLOCK PICHIA process development insights

VALIDOGEN is bringing UNLOCK PICHIA process development insights to the 11th Conference on Recombinant Protein Production, RPP11, October 17-19 ...

→ Details

102 14.09.2023

Meet us at

Upcoming conferences & exhibitions

→ Details

103 15.12.2021

Spotlight on VALIDOGEN’s strain and process development program

Spotlight on microbioreactors supporting Pichia protein production strain selection and bioreactor cultivation process development

→ Details

104 16.03.2021

VALIDOGEN to present at PICHIA 2021, online conference, March 24 - April 1

Pichia 2021, online conference "Don't miss latest insights into UNLOCK PICHIA technology developments"

→ Details

105 18.06.2020

New case study on VHH antibody expression underlines the power of UNLOCK PICHIA

We conducted a series of case studies, demonstrating the yield-enhancing effects of applying different toolbox elements of VALIDOGEN's Pichia ...

→ Details

106 05.06.2019

Spotlight on high-yield VHH expression using UNLOCK PICHIA

Benefit from the economic advantages of enhanced VHH production arising from the use of UNLOCK PICHIA

→ Details

107 22.10.2018

VTU Technology is now VALIDOGEN

→ Details

108 26.06.2017

What About Pichia?

Read our latest article "What about Pichia" reviewing recent advances in optimising Pichia European Biopharmaceutical Review July 2017, ...

→ Details

109 24.05.2016

Evercyte and VTU Technology collaborate on development of recombinant media supplements

Launch of first joint product – VEGF 165 for cell culture applications

→ Details

110 27.04.2016

VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration

→ Details

111 19.04.2016

Pichia production of albumin fusion proteins

→ Details

112 11.04.2016

VTU Technology and Biomay have signed license agreement

Biomay to apply VTU Pichia strains for the production of recombinant allergens

→ Details

113 10.02.2015

Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology

→ Details

114 03.12.2014

VTU Technology and RCT Announce Partnership

VTU Technology to offer unique combination of technologies for the high-level production of proteins with human-like glycosylation using Pichia ...

→ Details

115 04.07.2013

From Consulting Engineers to Technology Company

With more than 300 employees and 15 sites, VTU is now competing in the premier league of technology service providers.

→ Details

116 27.11.2012

VTU Technology and Minapharm Pharmaceuticals enter into development and license agreement

VTU Technology and Minapharm Pharmaceuticals announced today, that they have entered into a licensing agreement to develop a therapeutic, recombinant ...

→ Details

117 01.11.2012

VTU Technology featured in GEN - Genetic Engineering & Biotechnology News

→ Details

118 18.09.2012

DNA2.0 taps VTU Technology as Research Partner for Industrial Scale Protein Expression

DNA2.0 and VTU to Develop an Optimized Gene Design for Pichia Pastoris

→ Details

119 04.01.2012

Almac and VTU Technology form collaboration - broader range of contract services

Almac and VTU Technology form collaboration to provide customers with high yielding, fast-track generation of site-specific modified products

→ Details

120 04.12.2011

VTU Technology Launches Breakthrough Technology for High Level Methanol-free Protein Expression

VTU Technology, a leading contract research and development company providing services for the fast-track generation of high-performance industrial ...

→ Details

121 20.11.2011

Collaboration of Boehringer Ingelheim and VTU Technology in Technology and Marketing

Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive ...

→ Details

VALIDOGEN News

VALIDOGEN is giving UNLOCK PICHIA process development insights

Meet us at

Spotlight on VALIDOGEN’s strain and process development program

VALIDOGEN to present at PICHIA 2021, online conference, March 24 - April 1

New case study on VHH antibody expression underlines the power of UNLOCK PICHIA

Spotlight on high-yield VHH expression using UNLOCK PICHIA

VTU Technology is now VALIDOGEN

What About Pichia?

Evercyte and VTU Technology collaborate on development of recombinant media supplements

VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration

Pichia production of albumin fusion proteins

VTU Technology and Biomay have signed license agreement

Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology

VTU Technology and RCT Announce Partnership

From Consulting Engineers to Technology Company

VTU Technology and Minapharm Pharmaceuticals enter into development and license agreement

VTU Technology featured in GEN - Genetic Engineering & Biotechnology News

DNA2.0 taps VTU Technology as Research Partner for Industrial Scale Protein Expression

Almac and VTU Technology form collaboration - broader range of contract services

VTU Technology Launches Breakthrough Technology for High Level Methanol-free Protein Expression

Collaboration of Boehringer Ingelheim and VTU Technology in Technology and Marketing

News

VALIDOGEN is giving UNLOCK PICHIA process development insights

Meet us at

Press

Press center

Downloads

Company folder and brochures